Jonathan Weiss / Shutterstock.com

14 November 2024NewsEuropeMarisa Woutersen

GSK triumphs in EPO appeal, revoking Pfizer patent

European patent related to an inhaler revoked following successful appeal by GSK | Ruling comes after a series of challenges over novelty and inventive step | Decision further intensifies ongoing patent disputes between the pharma giants.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

GSK: Pfizer, BioNTech ‘reaped billions of dollars’ from stealing COVID-19 patents

26 April 2024 New claim from GlaxoSmithKline is latest in litany of lawsuits against rivals | US lawsuit, potentially worth “billions of dollars”, is filed as UK trial kicks off between Moderna, Pfizer and BioNTech.

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More features

BMS notches legal win and FDA nod

AstraZeneca fends off diabetes generic, for now

Patent pledges in global crises: Why Moderna prevailed over Pfizer/BioNTech

EPO: Biotech innovation strong, while pharma trails behind

LSPN chair: Uncertainty lies ahead for life sciences

UPC issues sweeping injunction against Meril in heart valve case

PierFerd taps pharma and biotech patent expert from Weiss & Arons

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant